摘要
<正>The 2018 Medicine Nobel Prize was awarded jointly to two immunologists, James P. Allison at the University of Texas MD Anderson Cancer Center in Houston and Tasuku Honjo at Kyoto University in Japan, who pioneered a new way to treat cancers (Ledford et al. 2018). Both Laureates have shown how so called ‘‘immune checkpoints’’ on T cells can be used to manipulate the immune responses so
引文
Akhmetzyanova I,Drabczyk M,Neff CP,Gibbert K,Dietze KK,Werner T,Liu J,Chen L,Lang KS,Palmer BE,Dittmer U,Zelinskyy G(2015)PD-L1 expression on retrovirus-infected cells mediates immune escape from CD8?T cell killing.PLoSPathog 11:e1005224
Barber DL,Wherry EJ,Masopust D,Zhu B,Allison JP,Sharpe AH,Freeman GJ,Ahmed R(2006)Restoring function in exhausted CD8?T cells during chronic viral infection.Nature439:682-687
Bengsch B,Martin B,Thimme R(2014)Restoration of HBV-specific CD8?T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation.J Hepatol61:1212-1219
Boni C,Fisicaro P,Valdatta C,Amadei B,Di Vincenzo P,Giuberti T,Laccabue D,Zerbini A,Cavalli A,Missale G,Bertoletti A,Ferrari C(2007)Characterization of hepatitis B virus(HBV)-specific T-cell dysfunction in chronic HBV infection.J Virol81:4215-4225
Brahmer JR,Drake CG,Wollner I,Powderly JD,Picus J,Sharfman WH,Stankevich E,Pons A,Salay TM,McMiller TL,Gilson MM,Wang C,Selby M,Taube JM,Anders R,Chen L,Korman AJ,Pardoll DM,Lowy I,Topalian SL(2010)Phase I study of single-agent anti-programmed death-1(MDX-1106)in refractory solid tumors:safety,clinical activity,pharmacodynamics,and immunologic correlates.J Clin Oncol 28:3167-3175
Burton AR,Pallett LJ,McCoy LE,Suveizdyte K,Amin OE,Swadling L,Alberts E,Davidson BR,Kennedy PT,Gill US,Mauri C,Blair PA,Pelletier N,Maini MK(2018)Circulating and intrahepatic antiviral B cells are defective in hepatitis B.J Clin Investig 128:4588-4603
Channappanavar R,Twardy BS,Suvas S(2012)Blocking of PDL-1interaction enhances primary and secondary CD8?T cell response to herpes simplex virus-1 infection.PLoS ONE7:e39757
Dietze KK,Zelinskyy G,Liu J,Kretzmer F,Schimmer S,Dittmer U(2013)Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virusspecific CD8?T cells and efficiently reduces chronic retroviral loads.PLoS Pathog 9:e1003798
Fisicaro P,Valdatta C,Massari M,Loggi E,Biasini E,Sacchelli L,Cavallo MC,Silini EM,Andreone P,Missale G,Ferrari C(2010)Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.Gastroenterology 138:682-693,693 e681-684
Fuller MJ,Callendret B,Zhu B,Freeman GJ,Hasselschwert DL,Satterfield W,Sharpe AH,Dustin LB,Rice CM,Grakoui A,Ahmed R,Walker CM(2013)Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1(PD-1).Proc Natl Acad Sci USA 110:15001-15006
Gane E,Gaggar A,Nguyen AH,Subramanian GM,McHutchison JG,Schwabe C,Dunbar R(2017)A phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients.J Hepatol 66:S26-S27
Gardiner D,Lalezari J,Lawitz E,DiMicco M,Ghalib R,Reddy KR,Chang KM,Sulkowski M,Marro SO,Anderson J,He B,Kansra V,McPhee F,Wind-Rotolo M,Grasela D,Selby M,Korman AJ,Lowy I(2013)A randomized,double-blind,placebo-controlled assessment of BMS-936558,a fully human monoclonal antibody to programmed death-1(PD-1),in patients with chronic hepatitis C virus infection.PLoS ONE 8:e63818
Garon EB,Rizvi NA,Hui R,Leighl N,Balmanoukian AS,Eder JP,Patnaik A,Aggarwal C,Gubens M,Horn L,Carcereny E,Ahn MJ,Felip E,Lee JS,Hellmann MD,Hamid O,Goldman JW,Soria JC,Dolled-Filhart M,Rutledge RZ,Zhang J,Lunceford JK,Rangwala R,Lubiniecki GM,Roach C,Emancipator K,Gandhi L,Investigators K-(2015)Pembrolizumab for the treatment of non-small-cell lung cancer.N Engl J Med372:2018-2028
Gay CL,Bosch RJ,Ritz J,Hataye JM,Aga E,Tressler RL,Mason SW,Hwang CK,Grasela DM,Ray N,Cyktor JC,Coffin JM,Acosta EP,Koup RA,Mellors JW,Eron JJ,Team ACTS(2017)Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1infected participants on suppressive antiretroviral therapy.J Infect Dis 215:1725-1733
Hamid O,Robert C,Daud A,Hodi FS,Hwu WJ,Kefford R,Wolchok JD,Hersey P,Joseph RW,Weber JS,Dronca R,Gangadhar TC,Patnaik A,Zarour H,Joshua AM,Gergich K,Elassaiss-Schaap J,Algazi A,Mateus C,Boasberg P,Tumeh PC,Chmielowski B,Ebbinghaus SW,Li XN,Kang SP,Ribas A(2013)Safety and tumor responses with lambrolizumab(anti-PD-1)in melanoma.N Engl J Med 369:134-144
Hodi FS,O’Day SJ,McDermott DF,Weber RW,Sosman JA,Haanen JB,Gonzalez R,Robert C,Schadendorf D,Hassel JC,Akerley W,van den Eertwegh AJ,Lutzky J,Lorigan P,Vaubel JM,Linette GP,Hogg D,Ottensmeier CH,Lebbe C,Peschel C,Quirt I,Clark JI,Wolchok JD,Weber JS,Tian J,Yellin MJ,Nichol GM,Hoos A,Urba WJ(2010)Improved survival with ipilimumab in patients with metastatic melanoma.N Engl JMed 363:711-723
Hryniewicz A,Boasso A,Edghill-Smith Y,Vaccari M,Fuchs D,Venzon D,Nacsa J,Betts MR,Tsai WP,Heraud JM,Beer B,Blanset D,Chougnet C,Lowy I,Shearer GM,Franchini G(2006)CTLA-4 blockade decreases TGF-beta,IDO,and viral RNA expression in tissues of SIVmac251-infected macaques.Blood 108:3834-3842
Ishida Y,Agata Y,Shibahara K,Honjo T(1992)Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily,upon programmed cell death.EMBO J 11:3887-3895
Jeon S,Rowe AM,Carroll KL,Harvey SAK,Hendricks RL(2018)PD-L1/B7-H1 inhibits viral clearance by macrophages in HSV-1-infected corneas.J Immunol 200:3711-3719
Kaufmann DE,Walker BD(2009)PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention.J Immunol 182:5891-5897
Krummel MF,Allison JP(1995)CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.J Exp Med182:459-465
Kwon ED,Hurwitz AA,Foster BA,Madias C,Feldhaus AL,Greenberg NM,Burg MB,Allison JP(1997)Manipulation of Tcell costimulatory and inhibitory signals for immunotherapy of prostate cancer.Proc Natl Acad Sci USA 94:8099-8103
Leach DR,Krummel MF,Allison JP(1996)Enhancement of antitumor immunity by CTLA-4 blockade.Science271:1734-1736
Ledford H,Else H,Warren M(2018)Cancer immunologists scoop medicine Nobel prize.Nature 562:20-21
Liu J,Zhang E,Ma Z,Wu W,Kosinska A,Zhang X,Moller I,Seiz P,Glebe D,Wang B,Yang D,Lu M,Roggendorf M(2014)Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.PLoS Pathog 10:e1003856
Palmer BE,Neff CP,Lecureux J,Ehler A,Dsouza M,RemlingMulder L,Korman AJ,Fontenot AP,Akkina R(2013)In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4?T cell levels in humanized mice.J Immunol190:211-219
Porichis F,Kwon DS,Zupkosky J,Tighe DP,McMullen A,Brockman MA,Pavlik DF,Rodriguez-Garcia M,Pereyra F,Freeman GJ,Kavanagh DG,Kaufmann DE(2011)Responsiveness of HIV-specific CD4 T cells to PD-1 blockade.Blood118:965-974
Powles T,Eder JP,Fine GD,Braiteh FS,Loriot Y,Cruz C,Bellmunt J,Burris HA,Petrylak DP,Teng SL,Shen X,Boyd Z,Hegde PS,Chen DS,Vogelzang NJ(2014)MPDL3280A(anti-PD-L1)treatment leads to clinical activity in metastatic bladder cancer.Nature 515:558-562
Salimzadeh L,Le Bert N,Dutertre CA,Gill US,Newell EW,Frey C,Hung M,Novikov N,Fletcher S,Kennedy PT,Bertoletti A(2018)PD-1 blockade partially recovers dysfunctional virusspecific B cells in chronic hepatitis B infection.J Clin Investig128:4573-4587
Sanmamed MF,Chen L(2018)A paradigm shift in cancer immunotherapy:from enhancement to normalization.Cell175:313-326
Schurich A,Khanna P,Lopes AR,Han KJ,Peppa D,Micco L,Nebbia G,Kennedy PT,Geretti AM,Dusheiko G,Maini MK(2011)Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection.Hepatology 53:1494-1503
Seung E,Dudek TE,Allen TM,Freeman GJ,Luster AD,Tager AM(2013)PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads.PLoS ONE 8:e77780
Topalian SL,Sznol M,McDermott DF,Kluger HM,Carvajal RD,Sharfman WH,Brahmer JR,Lawrence DP,Atkins MB,Powderly JD,Leming PD,Lipson EJ,Puzanov I,Smith DC,Taube JM,Wigginton JM,Kollia GD,Gupta A,Pardoll DM,Sosman JA,Hodi FS(2014)Survival,durable tumor remission,and longterm safety in patients with advanced melanoma receiving nivolumab.J Clin Oncol 32:1020-1030
Velu V,Titanji K,Zhu B,Husain S,Pladevega A,Lai L,Vanderford TH,Chennareddi L,Silvestri G,Freeman GJ,Ahmed R,Amara RR(2009)Enhancing SIV-specific immunity in vivo by PD-1blockade.Nature 458:206-210
Wykes MN,Lewin SR(2018)Immune checkpoint blockade in infectious diseases.Nat Rev Immunol 18:91-104
Zhang E,Zhang X,Liu J,Wang B,Tian Y,Kosinska AD,Ma Z,Xu Y,Dittmer U,Roggendorf M,Yang D,Lu M(2011)The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection.PLoS ONE 6:e26196
